Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06630234 · ClinicalTrials.gov registry record · Phase 1

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

A Phase 1 study of Gastrointestinal Stromal Tumor (GIST), sponsored by Deciphera Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
120
Enrollment target
10
Study locations

NCT06630234 is a Phase 1 study of Gastrointestinal Stromal Tumor (GIST) that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 120 participants, below the 174-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target (31% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06630234, a Phase 1 study of Gastrointestinal Stromal Tumor (GIST), is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.

Conditions Studied

Gastrointestinal Stromal Tumor (GIST)

Interventions

  • DRUG DCC-3009

Study Locations (10)

Florida

  • Mayo Clinic Florida - Jacksonville
  • University of Miami - Sylvester Comprehensive Cancer Center - Miami

Arizona

  • HonorHealth - Scottsdate

California

  • UC San Diego Moores Cancer Center - La Jolla

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • START Midwest - Grand Rapids

Minnesota

  • Mayo Clinic Rochester - Rochester

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-12-10
Est. Completion 2028-05
Phase Phase 1

Sponsor

Deciphera Pharmaceuticals

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06630234

The ClinicalTrials.gov registry entry for NCT06630234 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target (31% lower). The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Stromal Tumor (GIST) appearing as the primary indexed condition, and to 1 intervention - of which DCC-3009 is the first listed.

NCT06630234 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06630234 about?

NCT06630234 is a clinical study titled "A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)". The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer...

What is the current status of trial NCT06630234?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-12-10. Estimated completion is 2028-05.

What conditions does trial NCT06630234 study?

This clinical trial studies the following conditions: Gastrointestinal Stromal Tumor (GIST).

What interventions are being tested in trial NCT06630234?

The interventions under investigation include: DCC-3009 (DRUG).

Who is sponsoring clinical trial NCT06630234?

This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06630234 being conducted?

This trial has 10 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Stromal Tumor (GIST)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Stromal Tumor (GIST)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.